OBJECTIVES: The impact of pulmonary artery catheterization (PAC) on survival in patients with cardiogenic shock (CS) is not well established. This study aimed to assess whether Swan-Ganz catheter monitoring is related to short- and long-term mortality in patients with CS. METHODS: One hundred and twenty-nine consecutive patients with a first admission for CS were prospectively enrolled in a single-center registry between December 2005 and May 2009, and were subsequently followed up over 5.3 years. RESULTS: PAC was used in 64% of all patients with a mean age of 68 years (65% men). After adjustment for age, gender and the presence of CS upon admission, PAC was associated with lower short-term mortality [hazard ratio (HR) = 0.55, 95% confidence interval (CI) 0.35-0.86, p = 0.008] as well as lower mortality rates in the long-term follow-up (HR = 0.63, 95% CI 0.41-0.97, p = 0.035). In a subgroup analysis, the use of PAC was associated with reduced mortality in patients without acute coronary syndrome (ACS), i.e. 49% in the Swan-Ganz group vs. 82% (p = 0.010), but there was no difference within the ACS group. CONCLUSIONS: The use of PAC in patients with CS was associated with lower short- and long-term mortality rates after adjustment for age, gender and the presence of shock upon admission. This benefit was only significant in those patients without ACS.
OBJECTIVES: The impact of pulmonary artery catheterization (PAC) on survival in patients with cardiogenic shock (CS) is not well established. This study aimed to assess whether Swan-Ganz catheter monitoring is related to short- and long-term mortality in patients with CS. METHODS: One hundred and twenty-nine consecutive patients with a first admission for CS were prospectively enrolled in a single-center registry between December 2005 and May 2009, and were subsequently followed up over 5.3 years. RESULTS: PAC was used in 64% of all patients with a mean age of 68 years (65% men). After adjustment for age, gender and the presence of CS upon admission, PAC was associated with lower short-term mortality [hazard ratio (HR) = 0.55, 95% confidence interval (CI) 0.35-0.86, p = 0.008] as well as lower mortality rates in the long-term follow-up (HR = 0.63, 95% CI 0.41-0.97, p = 0.035). In a subgroup analysis, the use of PAC was associated with reduced mortality in patients without acute coronary syndrome (ACS), i.e. 49% in the Swan-Ganz group vs. 82% (p = 0.010), but there was no difference within the ACS group. CONCLUSIONS: The use of PAC in patients with CS was associated with lower short- and long-term mortality rates after adjustment for age, gender and the presence of shock upon admission. This benefit was only significant in those patients without ACS.
Authors: Alexander G Truesdell; Behnam Tehrani; Ramesh Singh; Shashank Desai; Patricia Saulino; Scott Barnett; Stephen Lavanier; Charles Murphy Journal: Interv Cardiol Date: 2018-05
Authors: Shiva P Ponamgi; Muhammad Haisum Maqsood; Pranathi R Sundaragiri; Michael G DelCore; Arun Kanmanthareddy; Wissam A Jaber; William J Nicholson; Saraschandra Vallabhajosyula Journal: World J Cardiol Date: 2021-12-26
Authors: Saraschandra Vallabhajosyula; Aditi Shankar; Sri Harsha Patlolla; Abhiram Prasad; Malcolm R Bell; Jacob C Jentzer; Shilpkumar Arora; Saarwaani Vallabhajosyula; Bernard J Gersh; Allan S Jaffe; David R Holmes; Shannon M Dunlay; Gregory W Barsness Journal: ESC Heart Fail Date: 2020-04-02
Authors: Sagar Ranka; Ioannis Mastoris; Navin K Kapur; Ryan J Tedford; Aniket Rali; Prakash Acharya; Robert Weidling; Amandeep Goyal; Andrew J Sauer; Bhanu Gupta; Nicholas Haglund; Kamal Gupta; James C Fang; JoAnn Lindenfeld; Zubair Shah Journal: J Am Heart Assoc Date: 2021-08-21 Impact factor: 5.501